The allocation of limited resources for health care should be based on the relative importance (or burden) of different conditions to the health of the nations. Mortality as a major public health indicator has had the effect of limiting the attention given to highly prevalent, seriously disabling but non-fatal disorders. Use of traditional measurement methods has led, in fact, to a serious underestimation of the relative importance of brain disorders worldwide, because they rarely cause death and because several of them produce severe and longterm disability but not death. The number of deaths does not take into consideration the non-fatal outcome of illness and prevalence rates do not take into consideration the severity and duration of disability produced by a disease. There is also increasing attention being paid to the shift from communicable disease to chronic, non-communicable diseases, the socalled "epidemiological transition", which is also related to the increase of life expectancy. Brain disorders contribute substantially to the overall disease burden of developed and developing societies, but this is generally underestimated by the public health community.
The socioeconomic impact of many brain disorders is wide ranging, long lasting and huge. These disorders impose a range of costs on individuals, families and communities as a whole. Part of this economic burden is obvious and measurable, while part is almost impossible to measure. Among the measurable components of the economic burden are health and social service needs, lost employment and reduced productivity, impact on families and caregivers, and the negative impact of premature mortality. Indirect costs arising from productivity loss account for a larger proportion of overall costs than direct costs.
All these estimates of economic evaluations are most certainly underestimates, as lost opportunity costs to individuals, families and societies are not taken into account, but are nevertheless vital to fully understanding the implications and the burden of brain disorder. WHO defines the "burden" of a disease including also the economic and emotional difficulties that the person as well as his/her family experiences as a result of it, as well as the lost opportunities, difficulties in achieving his/her full potential in work, social relationships and leisure.
As I think that, although headache disorders have their awareness week in September, as well as the WHA/IHS/WHO "Lifting the Burden Campaign", it is important for this Journal to invite its readers to implement awareness of brain disorders in general. More attention, more support and more funds for research on brain disorders will be useful to contribute to relief of the burden of headache sufferers as well as all those affected by pain.
